1. Home
  2. MBWM vs DRTS Comparison

MBWM vs DRTS Comparison

Compare MBWM & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mercantile Bank Corporation

MBWM

Mercantile Bank Corporation

N/A

Current Price

$60.40

Market Cap

998.5M

Sector

Finance

ML Signal

N/A

Logo Alpha Tau Medical Ltd.

DRTS

Alpha Tau Medical Ltd.

N/A

Current Price

$11.58

Market Cap

978.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MBWM
DRTS
Founded
1997
2015
Country
United States
Israel
Employees
N/A
121
Industry
Major Banks
Medical/Dental Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
998.5M
978.2M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
MBWM
DRTS
Price
$60.40
$11.58
Analyst Decision
Buy
Strong Buy
Analyst Count
3
3
Target Price
$55.67
$8.67
AVG Volume (30 Days)
119.2K
803.0K
Earning Date
04-21-2026
05-18-2026
Dividend Yield
3.08%
N/A
EPS Growth
10.95
N/A
EPS
1.32
N/A
Revenue
N/A
N/A
Revenue This Year
$20.28
N/A
Revenue Next Year
$4.67
$699.98
P/E Ratio
$44.41
N/A
Revenue Growth
N/A
N/A
52 Week Low
$42.75
$2.87
52 Week High
$60.40
$14.11

Technical Indicators

Market Signals
Indicator
MBWM
DRTS
Relative Strength Index (RSI) 64.18 45.79
Support Level $48.89 $11.51
Resistance Level N/A $14.00
Average True Range (ATR) 1.57 0.91
MACD 0.04 -0.21
Stochastic Oscillator 93.34 11.79

Price Performance

Historical Comparison
MBWM
DRTS

About MBWM Mercantile Bank Corporation

Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.

About DRTS Alpha Tau Medical Ltd.

Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.

Share on Social Networks: